Sign In
Buy AORT
$20.58
+0.160 (+0.784%)
At Close: Jun 03, 2026
Artivion: Reaffirm Hold As Pressures To Growth Remain
04:57am, Thursday, 20'th Apr 2023
Artivion: Reaffirm Hold As Pressures To Growth Remain.
Why Artivion Stock Popped on Friday
07:31pm, Friday, 17'th Feb 2023
There's nothing like an upside earnings surprise to juice the price of a company's shares.
Artivion, Inc. (AORT) Q4 2022 Earnings Call Transcript
09:42pm, Thursday, 16'th Feb 2023
Artivion, Inc. (NYSE:AORT ) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ET Company Participants Brian Johnston - Vice President at Gilmartin Group Pat Mackin - Chairman, President & CEO
Artivion (AORT) Q4 Earnings Surpass Estimates
07:34pm, Thursday, 16'th Feb 2023
Artivion (AORT) delivered earnings and revenue surprises of 158.82% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2022 Financial Results
08:30am, Thursday, 02'nd Feb 2023
ATLANTA , Feb. 2, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2022 fi
Artivion (AORT) Upgraded to Buy: What Does It Mean for the Stock?
01:33pm, Friday, 25'th Nov 2022
Artivion (AORT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Artivion, Inc. (AORT) Q3 2022 Earnings Call Transcript
05:02pm, Saturday, 05'th Nov 2022
Artivion, Inc. (NYSE:AORT ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Sam Bentzinger - Gilmartin Group Pat Mackin - Chairman, President & CEO Ashley Lee - EVP &
Artivion (AORT) Reports Q3 Loss, Tops Revenue Estimates
08:20pm, Thursday, 03'rd Nov 2022
Artivion (AORT) delivered earnings and revenue surprises of 54.55% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver
05:48pm, Tuesday, 27'th Sep 2022
Artivion, Inc.'s decision to pull the PROACT Xa trial resulted in heavy downside for the share price. Investors have sold positions rapidly such that the stock trades at multi-year lows.
Artivion to Present at the Deutsche Bank 30th Annual Leveraged Finance Conference
08:10am, Wednesday, 14'th Sep 2022
ATLANTA , Sept. 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deu
Artivion to Participate in Upcoming Investor Conferences
04:10pm, Tuesday, 06'th Sep 2022
ATLANTA , Sept. 6, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming
Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase
04:10pm, Wednesday, 24'th Aug 2022
ATLANTA , Aug. 24, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the upc
Artivion, Inc. (AORT) CEO James Mackin on Q2 2022 Results - Earnings Call Transcript
01:18am, Sunday, 07'th Aug 2022
Artivion, Inc. (NYSE:AORT ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group James Mackin - Chairman, President & CEO David Lee - EVP, C
Artivion (AORT) Soars 10.2%: Is Further Upside Left in the Stock?
09:16am, Thursday, 23'rd Jun 2022
Artivion (AORT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Artivion, Inc. (AORT) CEO Pat Mackin on Q1 2022 Results - Earnings Call Transcript
03:10am, Sunday, 08'th May 2022
Artivion, Inc. (NYSE:AORT ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Brian Johnston - Investor Relations Pat Mackin - Chief Executive Officer Ashley Lee - Chief Fin
